- Price
- $154.04
- Day
- -2.55%
- Mkt Cap
- $61.12B
- 52W Range
- $22.28 – $176.66
- Volume
- 20.24M
- Beta
- 0.90
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
As the bulls reassert their power, leading stocks like SanDisk, Coinbase, and Moderna are setting up in constructive base structures.
Read full article
The Fed hiked to 4%, Generac jumped 40% on Amazon warrants, and more
Read full article
Axsome Therapeutics is seeing significant revenue growth as its central nervous system portfolio gains commercial traction. Moderna is transitioning its mRNA platform toward a broader array of respiratory and oncology treatments to offset declining COVID-19 vaccine sales.
Read full article
Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once again on Thursday, extending one of the sharpest one-month runs in large-cap biotech this year without a fresh disclosure attached to it.
Read full article
Moderna, Inc‘s (NASDAQ:MRNA) biggest problem is no longer proving that its mRNA technology can work against cancer. Investors got that answer in August.
Read full article
Moderna Inc. (NASDAQ:MRNA) shares are popping Thursday, extending a month-long rally that began with a Phase 3 cancer vaccine breakthrough.
Read full article
Forgent reports bumper quarter, Nvidia joins the AI safety debate, and more
Read full article
Shares of Moderna MRNA have staged a remarkable comeback this year as investors increasingly warm to the possibility that the company can rebuild its business beyond COVID-19 vaccines. After becoming one of the biggest pandemic winners, Moderna struggled with sharply lower COVID-19 vaccine demand, declining revenues and mounting losses, sending its stock tumbling from its pandemic-era highs.
Read full article
AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033PR NewswireAUSTIN, Texas, Sept. 14, 2026AUSTIN, Texas, Sept. 14, 2026 /PRNewswire/ -- USA News
Read full article
Moderna's recent success in a phase 3 clinical trial for its personalized cancer vaccine was a breakthrough. This product could rival the lifetime sales of Moderna's coronavirus vaccine.
Read full article
Moderna NASDAQ: MRNA President Stephen Hoge said the company's recently announced positive Phase III results for its investigational personalized cancer vaccine, intismeran, in adjuvant melanoma support a broader effort to use T-cell priming in multiple tumor types.
Read full article
Moderna built an artificial intelligence that reads a patient's tumor and decides what that patient's medicine should be. That approach just cleared its biggest test.
Read full article